Daniel Slifkin Named to Benchmark Litigation’s “Hall of Fame”
March 14, 2024
On March 13, 2024, Benchmark Litigation named Cravath partner Daniel Slifkin to its “Hall of Fame” at the publication’s twelfth annual U.S. Awards, which were held in New York City. The awards recognize “the country’s most distinguished litigators and their firms for their exemplary work over the past twelve months.”
The Firm was also recognized with an “Impact Case Award” for its representation of client Amgen in its successful defense against an FTC challenge, securing clearance for its $27.8 billion acquisition of Horizon Therapeutics, and partner David R. Marriott received the “Trial Lawyer of the Year” award.
Related Practices & Industries
People
- Photo
-
-
J.D., 1991, Harvard Law SchoolSears Prize, magna cum laude
-
B.C.L., 1988, University of OxfordFirst Class Honors
-
B.A., 1987, University of OxfordFirst Class Honors
- New York
Education
Admitted In
Related News
Deals & Cases
September 11, 2023
Amgen Successfully Defends Against FTC Challenge, Securing Clearance for its $27.8 Billion Acquisition of Horizon Therapeutics
Cravath represented Amgen, one of the world’s largest biopharmaceutical companies, in successfully defending against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that The Wall Street Journal described as “a rare instance” of the FTC “throwing in the towel on litigation.”
